清晨好,您是今天最早来到科研通的研友!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您科研之路漫漫前行!

Stereotactic ablative radiotherapy with or without immunotherapy for early-stage or isolated lung parenchymal recurrent node-negative non-small-cell lung cancer: an open-label, randomised, phase 2 trial

离格 医学 放射治疗 肺癌 阶段(地层学) 打开标签 外科 薄壁组织 放射外科 内科学 放射科 肿瘤科 随机对照试验 癌症 病理 免疫疗法 古生物学 生物
作者
Joe Y. Chang,Steven H. Lin,Wenli Dong,Zhongxing Liao,Saumil Gandhi,Carl M. Gay,Jianjun Zhang,Stephen G. Chun,Yasir Y. Elamin,Frank V. Fossella,George R. Blumenschein,Tina Cascone,Xiuning Le,Jenny Vu Pozadzides,Anne S. Tsao,Vivek Verma,James W. Welsh,Aileen B. Chen,Mehmet Altan,Reza J. Mehran
出处
期刊:The Lancet [Elsevier BV]
卷期号:402 (10405): 871-881 被引量:121
标识
DOI:10.1016/s0140-6736(23)01384-3
摘要

Background Stereotactic ablative radiotherapy (SABR) is the standard treatment for medically inoperable early-stage non-small-cell lung cancer (NSCLC), but regional or distant relapses, or both, are common. Immunotherapy reduces recurrence and improves survival in people with stage III NSCLC after chemoradiotherapy, but its utility in stage I and II cases is unclear. We therefore conducted a randomised phase 2 trial of SABR alone compared with SABR with immunotherapy (I-SABR) for people with early-stage NSCLC. Methods We did an open-label, randomised, phase 2 trial comparing SABR to I-SABR, conducted at three different hospitals in TX, USA. People aged 18 years or older with histologically proven treatment-naive stage IA–IB (tumour size ≤4 cm, N0M0), stage IIA (tumour size ≤5 cm, N0M0), or stage IIB (tumour size >5 cm and ≤7 cm, N0M0) as per the American Joint Committee on Cancer version 8 staging system or isolated parenchymal recurrences (tumour size ≤7 cm) NSCLC (TanyNanyM0 before definitive surgery or chemoradiotherapy) were included in this trial. Participants were randomly assigned (1:1; using the Pocock & Simon method) to receive SABR with or without four cycles of nivolumab (480 mg, once every 4 weeks, with the first dose on the same day as, or within 36 h after, the first SABR fraction). This trial was unmasked. The primary endpoint was 4-year event-free survival (local, regional, or distant recurrence; second primary lung cancer; or death). Analyses were both intention to treat (ITT) and per protocol. This trial is registered with ClinicalTrials.gov (NCT03110978) and is closed to enrolment. Findings From June 30, 2017, to March 22, 2022, 156 participants were randomly assigned, and 141 participants received assigned therapy. At a median 33 months' follow-up, I-SABR significantly improved 4-year event-free survival from 53% (95% CI 42–67%) with SABR to 77% (66–91%; per-protocol population, hazard ratio [HR] 0·38; 95% CI 0·19–0·75; p=0·0056; ITT population, HR 0·42; 95% CI 0·22–0·80; p=0·0080). There were no grade 3 or higher adverse events associated with SABR. In the I-SABR group, ten participants (15%) had grade 3 immunologial adverse events related to nivolumab; none had grade 3 pneumonitis or grade 4 or higher toxicity. Interpretation Compared with SABR alone, I-SABR significantly improved event-free survival at 4 years in people with early-stage treatment-naive or lung parenchymal recurrent node-negative NSCLC, with tolerable toxicity. I-SABR could be a treatment option in these participants, but further confirmation from a number of currently accruing phase 3 trials is required. Funding Bristol-Myers Squibb and MD Anderson Cancer Center Alliance, National Cancer Institute at the National Institutes of Health through Cancer Center Core Support Grant and Clinical and Translational Science Award to The University of Texas MD Anderson Cancer Center.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
赧赧完成签到 ,获得积分10
3秒前
木南完成签到 ,获得积分10
10秒前
wang完成签到,获得积分10
23秒前
望向天空的鱼完成签到 ,获得积分10
32秒前
健康的大船完成签到 ,获得积分10
39秒前
armpit完成签到,获得积分10
40秒前
56秒前
12A完成签到,获得积分10
57秒前
k001boyxw完成签到,获得积分10
1分钟前
你才是小哭包完成签到 ,获得积分10
1分钟前
酱豆豆完成签到 ,获得积分10
2分钟前
小二郎应助科研通管家采纳,获得10
2分钟前
深情安青应助科研通管家采纳,获得10
2分钟前
2分钟前
忘忧Aquarius完成签到,获得积分10
3分钟前
共享精神应助科研通管家采纳,获得10
4分钟前
充电宝应助科研通管家采纳,获得10
4分钟前
火之高兴完成签到 ,获得积分10
4分钟前
平常的三问完成签到 ,获得积分10
4分钟前
河豚不擦鞋完成签到 ,获得积分10
4分钟前
可夫司机完成签到 ,获得积分10
4分钟前
4分钟前
彩色亿先完成签到 ,获得积分10
4分钟前
kean1943完成签到,获得积分10
4分钟前
万晓博发布了新的文献求助30
4分钟前
芒果完成签到 ,获得积分10
5分钟前
万晓博完成签到,获得积分20
5分钟前
5分钟前
6分钟前
6分钟前
小二郎应助科研通管家采纳,获得10
6分钟前
科研通AI2S应助科研通管家采纳,获得10
6分钟前
情怀应助科研通管家采纳,获得10
6分钟前
小白发布了新的文献求助10
6分钟前
搜集达人应助lty采纳,获得10
6分钟前
6分钟前
lty完成签到,获得积分10
6分钟前
lty发布了新的文献求助10
6分钟前
6分钟前
王翎力完成签到,获得积分10
6分钟前
高分求助中
A new approach to the extrapolation of accelerated life test data 1000
Cognitive Neuroscience: The Biology of the Mind 1000
Technical Brochure TB 814: LPIT applications in HV gas insulated switchgear 1000
Immigrant Incorporation in East Asian Democracies 600
Nucleophilic substitution in azasydnone-modified dinitroanisoles 500
不知道标题是什么 500
A Preliminary Study on Correlation Between Independent Components of Facial Thermal Images and Subjective Assessment of Chronic Stress 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3968521
求助须知:如何正确求助?哪些是违规求助? 3513341
关于积分的说明 11167298
捐赠科研通 3248700
什么是DOI,文献DOI怎么找? 1794417
邀请新用户注册赠送积分活动 875030
科研通“疑难数据库(出版商)”最低求助积分说明 804664